This poster presentation outlines Rush University Medical Center’s experience in treating FLC patients with a gemcitabine-oxaliplatin-lenvatanib (GEMOX-LEN) combination. This study describes the experiences of 16 patients, most of whom had multiple prior surgeries and systemic therapies, who were judged unresectable. The Rush University team chose gemcitabine-oxaliplatin (GEMOX) based on case reports of GEMOX efficacy in FLC, and combined it with the antiangiogenic/multi-kinase inhibitor lenvatanib. This combination was based on a treatment approach in the Children’s Oncology Group (COG) clinical trial AHEP1531 that uses a GEMOX-sorafenib combination, but substitutes lenvatanib for sorafenib based on an expectation of lower toxicity and more efficacy.
While the data is preliminary and uncontrolled, they found the combination to be a very promising option for FLC treatment in patients who are not surgical candidates, are widely metastatic or who have relapsed or progressed multiple times.
The poster is included below: